Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?

Steven E. Schild, Deepti Behl, Svetomir Nenad Markovic, Paul D. Brown, Jonathan R. Sande, Richard L. Deming, Kendrith M. Rowland, James D. Bearden

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma. Methods: Seven patients with brain metastases from melanoma were treated on a North Central Cancer Treatment Group (NCCTG) trial (N0274) of TMZ plus WBRT. TMZ was given orally in doses of 200 mg/m2 for 5 days every 4 weeks for up to 8 cycles. WBRT was started on the first day of TMZ and included the delivery of 3750 cGy in 15 fractions. In addition, separately analyzed was a cohort of 53 patients treated at the Mayo Clinic who received WBRT alone (39 patients) or WBRT plus TMZ (14 patients). Results: The median survival of the 7 patients treated on N0274 was 3.6 months with 2 of 7 (29%) failing in brain and 5 of 7 (71%) failing elsewhere. For the other cohort of 53 patients, the median survival was 3.8 months with WBRT alone compared 4.3 months for WBRT plus TMZ (P = 0.5). Conclusions: Patients did not appear to benefit from the addition of TMZ to WBRT for the treatment of their brain metastases. Further improvements in outcome will require research to discover more effective systemic therapy and RT techniques.

Original languageEnglish (US)
Pages (from-to)633-636
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

temozolomide
Melanoma
Radiotherapy
Neoplasm Metastasis
Brain

Keywords

  • Brain metastases
  • Combined modality therapy
  • Melanoma
  • Temozolomide
  • Whole brain radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brain metastases from melanoma : Is there a role for concurrent temozolomide in addition to whole brain radiation therapy? / Schild, Steven E.; Behl, Deepti; Markovic, Svetomir Nenad; Brown, Paul D.; Sande, Jonathan R.; Deming, Richard L.; Rowland, Kendrith M.; Bearden, James D.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 6, 12.2010, p. 633-636.

Research output: Contribution to journalArticle

Schild, Steven E. ; Behl, Deepti ; Markovic, Svetomir Nenad ; Brown, Paul D. ; Sande, Jonathan R. ; Deming, Richard L. ; Rowland, Kendrith M. ; Bearden, James D. / Brain metastases from melanoma : Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2010 ; Vol. 33, No. 6. pp. 633-636.
@article{189561bae6a644d3aedbbb36b8090013,
title = "Brain metastases from melanoma: Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?",
abstract = "Objectives: This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma. Methods: Seven patients with brain metastases from melanoma were treated on a North Central Cancer Treatment Group (NCCTG) trial (N0274) of TMZ plus WBRT. TMZ was given orally in doses of 200 mg/m2 for 5 days every 4 weeks for up to 8 cycles. WBRT was started on the first day of TMZ and included the delivery of 3750 cGy in 15 fractions. In addition, separately analyzed was a cohort of 53 patients treated at the Mayo Clinic who received WBRT alone (39 patients) or WBRT plus TMZ (14 patients). Results: The median survival of the 7 patients treated on N0274 was 3.6 months with 2 of 7 (29{\%}) failing in brain and 5 of 7 (71{\%}) failing elsewhere. For the other cohort of 53 patients, the median survival was 3.8 months with WBRT alone compared 4.3 months for WBRT plus TMZ (P = 0.5). Conclusions: Patients did not appear to benefit from the addition of TMZ to WBRT for the treatment of their brain metastases. Further improvements in outcome will require research to discover more effective systemic therapy and RT techniques.",
keywords = "Brain metastases, Combined modality therapy, Melanoma, Temozolomide, Whole brain radiotherapy",
author = "Schild, {Steven E.} and Deepti Behl and Markovic, {Svetomir Nenad} and Brown, {Paul D.} and Sande, {Jonathan R.} and Deming, {Richard L.} and Rowland, {Kendrith M.} and Bearden, {James D.}",
year = "2010",
month = "12",
doi = "10.1097/COC.0b013e3181c4c54b",
language = "English (US)",
volume = "33",
pages = "633--636",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Brain metastases from melanoma

T2 - Is there a role for concurrent temozolomide in addition to whole brain radiation therapy?

AU - Schild, Steven E.

AU - Behl, Deepti

AU - Markovic, Svetomir Nenad

AU - Brown, Paul D.

AU - Sande, Jonathan R.

AU - Deming, Richard L.

AU - Rowland, Kendrith M.

AU - Bearden, James D.

PY - 2010/12

Y1 - 2010/12

N2 - Objectives: This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma. Methods: Seven patients with brain metastases from melanoma were treated on a North Central Cancer Treatment Group (NCCTG) trial (N0274) of TMZ plus WBRT. TMZ was given orally in doses of 200 mg/m2 for 5 days every 4 weeks for up to 8 cycles. WBRT was started on the first day of TMZ and included the delivery of 3750 cGy in 15 fractions. In addition, separately analyzed was a cohort of 53 patients treated at the Mayo Clinic who received WBRT alone (39 patients) or WBRT plus TMZ (14 patients). Results: The median survival of the 7 patients treated on N0274 was 3.6 months with 2 of 7 (29%) failing in brain and 5 of 7 (71%) failing elsewhere. For the other cohort of 53 patients, the median survival was 3.8 months with WBRT alone compared 4.3 months for WBRT plus TMZ (P = 0.5). Conclusions: Patients did not appear to benefit from the addition of TMZ to WBRT for the treatment of their brain metastases. Further improvements in outcome will require research to discover more effective systemic therapy and RT techniques.

AB - Objectives: This study was performed to evaluate the addition of temozolomide (TMZ) to whole brain radiotherapy (WBRT) for brain metastases from melanoma. Methods: Seven patients with brain metastases from melanoma were treated on a North Central Cancer Treatment Group (NCCTG) trial (N0274) of TMZ plus WBRT. TMZ was given orally in doses of 200 mg/m2 for 5 days every 4 weeks for up to 8 cycles. WBRT was started on the first day of TMZ and included the delivery of 3750 cGy in 15 fractions. In addition, separately analyzed was a cohort of 53 patients treated at the Mayo Clinic who received WBRT alone (39 patients) or WBRT plus TMZ (14 patients). Results: The median survival of the 7 patients treated on N0274 was 3.6 months with 2 of 7 (29%) failing in brain and 5 of 7 (71%) failing elsewhere. For the other cohort of 53 patients, the median survival was 3.8 months with WBRT alone compared 4.3 months for WBRT plus TMZ (P = 0.5). Conclusions: Patients did not appear to benefit from the addition of TMZ to WBRT for the treatment of their brain metastases. Further improvements in outcome will require research to discover more effective systemic therapy and RT techniques.

KW - Brain metastases

KW - Combined modality therapy

KW - Melanoma

KW - Temozolomide

KW - Whole brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=78649998499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649998499&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181c4c54b

DO - 10.1097/COC.0b013e3181c4c54b

M3 - Article

C2 - 20042969

AN - SCOPUS:78649998499

VL - 33

SP - 633

EP - 636

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 6

ER -